Hong Kong Professional Services Stock News

Hansoh Pharmaceutical Group (SEHK:3692) just announced that China’s National Medical Products Administration has accepted its New Drug Application for HS-10365 capsules, targeting RET fusion-positive non-small cell lung cancer. This regulatory milestone may draw investor attention given its pipeline implications. See our latest analysis for Hansoh Pharmaceutical Group. Hansoh Pharmaceutical Group’s latest regulatory news comes amid a year of remarkable momentum, with the share price up a huge...

BYD (SEHK:1211) reported five-year annualized earnings growth of 47.1%, while more recent annual growth sits at 13.1%. With earnings projected to climb 18.84% per year and revenue expected to increase by 12.4% annually, both outpacing Hong Kong market averages, investors are watching these growth metrics closely. Net profit margins came in at 4.6%, down a touch from last year’s 5%, reflecting ongoing pressure but leaving room for optimism about forward momentum. See our full analysis for...

China Unicom (Hong Kong) (SEHK:762) just released its latest earnings, reporting higher revenue and net income for the nine months ended September 2025 compared to last year. The company also updated investors about its growing subscriber and network numbers. See our latest analysis for China Unicom (Hong Kong). Momentum has been strong for China Unicom (Hong Kong), with its recent results reflected not just in the books, but also in investor sentiment. The company’s share price has climbed...

Kingsoft (SEHK:3888) is in the spotlight after its subsidiary Beijing Kingsoft Office Software posted strong revenue and profit gains for the first nine months of 2025. This highlights effective execution and strengthens its financial position. See our latest analysis for Kingsoft. Kingsoft’s latest numbers surface just as the company rides a wave of optimism, with software policy shifts in China providing added momentum. The share price has gained 5.81% year-to-date, but what really stands...

Postal Savings Bank of China (SEHK:1658) delivered 13.7% earnings growth this year, outpacing its longer-term profit growth of 5.1% per year over the past five years. Net profit margins climbed from 23.8% to 26.9% and shares now trade at HK$5.48, still significantly below the discounted cash flow fair value estimate of HK$9.87. Investors have seen a string of high-quality results, with ongoing revenue and profit growth driving improved profitability, even as earnings forecasts remain a touch...

AIA Group Limited recently reported a record 25% rise in its third-quarter 2025 value of new business, with double-digit growth led by Hong Kong, Mainland China, ASEAN, and India. This result was driven by a record agency value of new business and an 18% increase in recruitment, reflecting the company's strong distribution capabilities in Asian markets. We'll examine how AIA Group's record growth in new business value influences its investment outlook and long-term earnings narrative. These...

CARsgen Therapeutics Holdings recently announced encouraging results from clinical trials of its CAR-T therapies for solid tumors and plasma cell leukemia, while also commencing a share repurchase program covering up to 10% of issued share capital as mandated by its shareholders. This combination of promising clinical advancements in immuno-oncology and capital management initiatives sets the company apart in a highly competitive sector. We’ll explore how the initiation of a large share...

Innovent Biologics recently reported third quarter 2025 product revenue exceeding RMB 3.3 billion, achieving around 40% year-on-year growth driven by both oncology and newly launched biomedicine therapies, including mazdutide and SINTBILO®. The company also announced positive Phase 3 results for mazdutide, showing it surpassed semaglutide in both glycemic and weight reduction outcomes for Chinese patients with type 2 diabetes and obesity, highlighting a potential new-generation treatment...

Weichai Power (SEHK:2338) reported another year of earnings growth, with net profit margins improving to 5.3% from 5.1% and annual earnings rising by 8.8%, outpacing its five-year average of 5.6% a year. Looking ahead, forecasts point to annual earnings growth of 10.92% and revenue gains of 5.8% per year. Trading at a price-to-earnings ratio of 10.6x, which stands below both the peer average and industry levels, the stock offers investors a margin story supported by solid profitability...

Li Ning Company Limited held its Q3 2025 earnings call on October 24, 2025, sharing updated financial performance and business developments for the quarter. This earnings update offered investors a window into the company's progress in digital channels and evolving response to consumer and market trends in China's sportswear sector. We will explore how the most recent earnings call sheds light on Li Ning's progress in digital transformation and margin management efforts. Explore 28 top...

CSPC Pharmaceutical Group (SEHK:1093) has just made headlines with two R&D milestones. Its JSKN003 therapy gained Breakthrough Therapy Designation for advanced colorectal cancer, and SYH2061 secured clearance for clinical trials in China. See our latest analysis for CSPC Pharmaceutical Group. After a stellar run earlier this year, CSPC Pharmaceutical Group’s share price recently cooled off, dropping 18.4% over the past month and 22.7% in the last 90 days. Still, its year-to-date share price...

Everest Medicines (SEHK:1952) has secured exclusive rights to develop and commercialize VIS-101, a promising bifunctional treatment for eye conditions like wet AMD, across Greater China and parts of Asia. This strategic move underscores the company’s ambitions in ophthalmology and signals potential growth ahead. See our latest analysis for Everest Medicines. Everest Medicines’ exclusive VIS-101 deal adds momentum to a year already marked by strong long-term performance. The company posted an...

Akeso (SEHK:9926) was in the spotlight after recently published Phase III HARMONi-6 study results showed its bispecific antibody, ivonescimab, plus chemotherapy significantly improved progression-free survival in advanced squamous NSCLC compared to current treatments. See our latest analysis for Akeso. Akeso’s big clinical win comes after a year of remarkable momentum, with a year-to-date share price return of 93.5% and a 66.3% total shareholder return over the past twelve months. Excitement...

Key Insights Significant insider control over VCREDIT Holdings implies vested interests in company growth 51% of the...

China Gingko Education Group Company Limited ( HKG:1851 ) shareholders would be excited to see that the share price has...

Key Insights The projected fair value for CMON is HK$0.044 based on 2 Stage Free Cash Flow to Equity With HK$0.04 share...

Unfortunately for some shareholders, the Shandong Hi-Speed Holdings Group Limited ( HKG:412 ) share price has dived 54...

Key Insights Man Wah Holdings' significant insider ownership suggests inherent interests in company's expansion Man Li...

Following the solid earnings report from China National Building Material Company Limited ( HKG:3323 ), the market...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

It is hard to get excited after looking at China Medical System Holdings' (HKG:867) recent performance, when its stock...

Despite the fact that China Dredging Environment Protection Holdings Limited (HKG:871) stock rose 11% last week...

Yoho Group Holdings Limited ( HKG:2347 ) shareholders won't be pleased to see that the share price has had a very rough...

Most readers would already be aware that Global New Material International Holdings' (HKG:6616) stock increased...